Retrospective cohort study shows preoperative AFP-L3 and PIVKA-II predict early recurrence in HCC, indicating temporal specificity.
Background/Aims: agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) independently predicts early recurrence and whether this association is temporally specific. Methods: This retrospective cohort study included 431 patients who underwent curative resection for HCC between 2010 and 2023 at a single tertiary center. Dual positivity was defined as AFP-L3 ≥15% and PIVKA-II ≥100 mAU/mL. The primary outcome was early recurrence-free survival. Late recurrence was assessed using landmark analysis in patients who were recurrencefree at 24 months (n=258). Multivariable Cox proportional hazards regression was performed adjusting for clinical and tumor characteristics. Results: During a median follow-up of 36.0 months, 100 patients (23.2%) developed early recurrence and 73 (16.9%) developed late recurrence. Dual positivity was independently associated with early recurrence (hazard ratio [HR], 2.38; 95% confidence interval [CI], 1.44 to 3.93; p<0.001) but not with late recurrence (HR, 0.92; 95% CI, 0.39 to 2.15; p=0.844). The 24-month cumulative incidence of recurrence was 39.2% for dual-positive patients compared with 19.2% in the low-risk group. This association remained consistent across sensitivity analyses using alternative biomarker cutoffs and across most clinical subgroups. Conclusions: Preoperative dual positivity for AFP-L3 and PIVKA-II was associated with early but not late recurrence after curative resection for HCC, suggesting temporal specificity of this biomarker combination. Prospective validation studies are warranted.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: